ArticleInternational journal of molecular sciences2011
Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies.
Article in International journal of molecular sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 119 citations in OpenAlex.
- Development of Voriconazole Proliposome Based Dry Powder for Inhalation: A Design of Experiment Approach.Pharmaceutics · 2025Article
- Engineering Inhalable Therapeutic Particles: Conventional and Emerging Approaches.Pharmaceutics · 2023Review
- A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation.Drug delivery and translational research · 2023Review
- An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Application of Lipid-Based Nanocarriers for Antitubercular Drug Delivery: A Review.Pharmaceutics · 2021Review
- Dry Powder for Pulmonary Delivery: A Comprehensive Review.Pharmaceutics · 2020Review
- Novel Approaches for the Treatment of Pulmonary Tuberculosis.Pharmaceutics · 2020Review
- Design of novel proliposome formulation for antioxidant peptide, glutathione with enhanced oral bioavailability and stability.Drug delivery · 2019Article
- Encapsulation of Isoniazid-conjugated Phthalocyanine-In-Cyclodextrin-In-Liposomes Using Heating Method.Scientific reports · 2019Article
- Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation.Pharmaceutics · 2019Article
- Discovery of a New Xanthone against Glioma: Synthesis and Development of (Pro)liposome Formulations.Molecules (Basel, Switzerland) · 2019Article
- The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases.Frontiers in immunology · 2018Review
- MicroRNAs as therapeutics for future drug delivery systems in treatment of lung diseases.Drug delivery and translational research · 2017Review
- Aggregated Nanotransfersomal Dry Powder Inhalation of Itraconazole for Pulmonary Drug Delivery.Advanced pharmaceutical bulletin · 2016Article
- Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery Systems.Journal of drug delivery · 2016Review
- Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2016Review
- Levofloxacin-proliposomes: opportunities for use in lung tuberculosis.Pharmaceutics · 2012Article
- Lipoidal soft hybrid biocarriers of supramolecular construction for drug delivery.ISRN pharmaceutics · 2012Article
- Preparation, in vitro characterization, and in vivo pharmacokinetic evaluation of respirable porous microparticles containing rifampicin.Scientia pharmaceuticaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aims of this study were to develop proliposome powders containing isoniazid (INH) in a dry powder aerosol form. INH-proliposome powders were prepared by a spray drying method. Proliposome physicochemical properties were determined using cascade impactor, X-ray diffraction and differential scanning calorimetry. The toxicity of proliposomes to respiratory-associated cell lines and its potential to provoke immunological responses from alveolar macrophages (AM) were determined. Free INH and INH-proliposome bioactivities were tested in vitro and in AM infected with Mycobacterium bovis (M. bovis). Aerosolization properties of INH-proliposome powders at 60 L/min, the powders showed mass median aerodynamic diameters of 2.99-4.92 μm, with fine particle fractions (aerosolized particles less than 4.4 μm) of 15-35%. Encapsulation of INH was 18-30%. Proliposome formulations containing INH to mannitol ratios of 4:6 and 6:4 exhibited the greatest overlapping peak between the drug and mannitol. INH-proliposomes were evidently nontoxic to respiratory-associated cells, and did not activate AM to produce inflammatory mediators-including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and nitric oxide-at a toxic level. The efficacy of INH-proliposome against AM infected with M. bovis was significantly higher than that of free INH (p < 0.05). INH-proliposomes are potential candidates for an alternative tuberculosis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.